# US 2025/0026750 A1 · Sulfoximine-containing atr inhibitor compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0026750 A1
- Document ID: US20250026750A1
- Status: Published application
- Kind: A1
- Application number: 18/569,592
- Filed: 2022-05-12
- Published: 2025-01-23
- Earliest claimed: 2021-05-12
- Assignees: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Applicants: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Inventors: Yinsheng ZHANG; Yan ZHU; Baomin LIU; Kuo GAI; Shawei CHEN; Wei SHI
- Web page: https://patentgrep.com/patent/US20250026750A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A sulfoximine-containing ATR inhibitor compound as represented by formula (I), a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the treatment of ATR-related or ATR-mediated diseases and/or conditions.

## Claims

### Claim 1

A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof,
wherein
is a double bond, X is selected from CRa, and Y is selected from N; or, is a single bond, X is selected from C═O, and Y is selected from NRb;
Ra is selected from the group consisting of hydrogen, hydroxy, cyano, halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-10 cycloalkyl, 3-10 membered heterocycloalkyl and C3-10 cycloalkyl-C2-6 alkynyl, wherein the C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-10 cycloalkyl, 3-10 membered heterocycloalkyl and C3-10 cycloalkyl-C2-6 alkynyl are optionally substituted with one or more halogen, hydroxy or cyano substituents;
Rb is selected from the group consisting of hydrogen and C1-6 alkyl;
R1 and R2 are each independently selected from the group consisting of C1-10 alkyl, C3-10 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 membered aryl and 5-10 membered heteroaryl, wherein the C3-10 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 membered aryl and 5-10 membered heteroaryl are optionally substituted with one or more Rc;
or R1 and R2, together with the sulfur atom to which they are attached, form 3-10 membered heterocyclyl, and the 3-10 membered heterocyclyl is optionally substituted with one or more Rd;
Rc and Rd are each independently selected from the group consisting of halogen, hydroxy, amino, C1-6 alkyl, C1-6 alkoxy, C1-6 alkyl-C(O)—, C1-6 alkyl-S(O)2—, C3-10 cycloalkyl, 3-10 membered heterocycloalkyl, C6-10 membered aryl and 5-10 membered heteroaryl;
R3 is selected from 5-10 membered heteroaryl optionally substituted with one or more Re;
Re is selected from the group consisting of hydroxy, amino, halogen, C1-6 alkyl, C1-3 haloalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein Ra is selected from the group consisting of hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl and C3-10 cycloalkyl-C2-6 alkynyl, wherein the C1-6 alkyl, C1-6 alkoxy, C3-10 cycloalkyl and C3-10 cycloalkyl-C2-6 alkynyl are optionally substituted with one or more halogens;
or Ra is selected from the group consisting of hydrogen, hydroxy, halogen and C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with one or more halogens;
or Ra is selected from the group consisting of hydrogen, hydroxy, halogen and C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with one or more halogens;
or Ra is selected from the group consisting of hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl and C3-6 cycloalkyl-C2-4 alkynyl, wherein the C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl and C3-6 cycloalkyl-C2-4 alkynyl are optionally substituted with one or more halogens;
or Ra is selected from the group consisting of hydrogen, bromine, methyl, n-propyl, isobutyl, tert-butyl, methoxy, cyclopropyl and cyclopropylethynyl, wherein the methyl, n-propyl, isobutyl, tert-butyl, methoxy, cyclopropyl and cyclopropylethynyl are optionally substituted with one or more halogens;
or Ra is selected from the group consisting of hydrogen, bromine, methyl, trifluoromethyl, 3,3,3-trifluoropropyl, isobutyl, tert-butyl, difluoromethoxy, cyclopropyl and cyclopropylethynyl;
or Ra is selected from the group consisting of hydrogen and bromine.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein Rb is selected from the group consisting of hydrogen and C1-3 alkyl;
or Rb is selected from hydrogen.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein is a double bond, X is selected from the group consisting of CH and CBr, and Y is selected from N.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein is a single bond, X is selected from C═O, and Y is selected from NH.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R1 and R2 are each independently selected from the group consisting of C1-6 alkyl, C3-8 cycloalkyl, 3-8 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl, wherein the C3-8 cycloalkyl, 3-8 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are optionally substituted with one or more Rc;
or R1 and R2 are each independently selected from the group consisting of C1-4 alkyl, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl, wherein the C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl are optionally substituted with one or more Rc;
or R1 and R2 are each independently selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, thienyl, pyridinyl, pyrimidinyl and furanyl, wherein the cyclopropyl, cyclopentyl, cyclohexyl, phenyl, pyrrolyl, thienyl, pyridinyl, pyrimidinyl or furanyl is optionally substituted with one or more Rc;
optionally, R1 and R2 are each independently selected from the group consisting of C1-3 alkyl, C3-4 cycloalkyl, phenyl and 5-6 membered heteroaryl, wherein the C3-4 cycloalkyl, phenyl and 5-6 membered heteroaryl are optionally substituted with one or more R;
or R1 and R2 are each independently selected from the group consisting of methyl, ethyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl and pyridinyl, wherein the cyclopropyl, cyclopentyl, cyclohexyl, phenyl and pyridinyl are optionally substituted with one or more Rc;
or R1 and R2 are each independently selected from the group consisting of methyl, ethyl, cyclopropyl, phenyl and pyridinyl.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein Rc and Rd are each independently selected from the group consisting of halogen, hydroxy, amino, C1-4 alkyl, C1-4 alkoxy, C1-4 alkyl-C(O)—, C1-4 alkyl-S(O)2—, C3-8 cycloalkyl, 3-8 membered heterocycloalkyl, C6-8 membered aryl and 5-8 membered heteroaryl;
or Rc and Rd are each independently selected from the group consisting of halogen, hydroxy, amino, C1-3 alkyl, C1-3 alkoxy, C1-3 alkyl-C(O)—, C1-3 alkyl-S(O)2—, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl;
or Rc and Rd are each independently selected from the group consisting of fluorine, chlorine, bromine, hydroxy, amino, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, CH3C(O)—, CH3CH2C(O)—, CH3CH2CH2C(O)—, (CH3)2CH(O)—, CH3S(O)2—, CH3CH2S(O)2—, CH3CH2CH2S(O)2—, (CH3)2CHS(O)2—, cyclopropyl, cyclopentyl, cyclohexyl, tetrahydrofuranyl, tetrahydropyrrolyl, piperazinyl, piperidinyl, phenyl, furanyl, pyrrolyl, thienyl, pyridinyl and pyrimidinyl;
optionally, Rc and Rd are each independently selected from the group consisting of halogen, hydroxy, amino, C1-4 alkyl and C1-4 alkoxy;
or Rc and Rd are each independently selected from the group consisting of halogen, hydroxy, amino, C1-3 alkyl and C1-3 alkoxy;
or Rc and Rd are each independently selected from the group consisting of halogen and C1-3 alkyl.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein R1 and R2, together with the sulfur atom to which they are attached, form 4-, 5-, 6-, 7-, 8-, 9- or 10-membered heterocycloalkyl, and the heterocycloalkyl is optionally substituted with one or more Rd;
or R1 and R2, together with the sulfur atom to which they are attached, form 4-6 membered mono heterocycloalkyl or 7-10 membered spiro heterocycloalkyl, and the mono heterocycloalkyl or spiro heterocycloalkyl is optionally substituted with one or more Rd;
or R1 and R2, together with the sulfur atom to which they are attached, form 4-, 5- or 6-membered mono heterocycloalkyl, or 7- or 9-membered spiro heterocycloalkyl, and the mono heterocycloalkyl or spiro heterocycloalkyl is optionally substituted with 1, 2 or 3 Rd;
or R1 and R2, together with the sulfur atom to which they are attached, form
or R1 and R2, together with the sulfur atom to which they are attached, form

### Claim 9 (depends on 1)

The compound according to claim 1, wherein R3 is selected from 5-6 membered heteroaryl optionally substituted with one or more Re;
or R3 is selected from 5-membered heteroaryl optionally substituted with one or more Re;
or R3 is selected from 5-membered N-containing heteroaryl optionally substituted with one or more Re;
or R3 is selected from pyrazolyl optionally substituted with one or more Re;
or R3 is selected from pyrazolyl optionally substituted with one Re;
or R3 is selected from the group consisting of
or R3 is selected from the group consisting of
or R3 is selected from the group consisting of
or R3 is selected from

### Claim 10 (depends on 1)

The compound according to claim 1, wherein Re is selected from the group consisting of hydroxy, amino, halogen, C1-3 alkyl, C1-3 haloalkyl, C3-6 cycloalkyl and 3-6 membered heterocycloalkyl;
or Re is selected from the group consisting of C1-3 alkyl, C1-3 haloalkyl and C3-6 cycloalkyl;
or Re is selected from the group consisting of methyl, trifluoromethyl and cyclopropyl.

### Claim 11 (depends on 1)

The compound of formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, being selected from a compound of formula (II) or formula (III), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
wherein
R1, R2, Rb and Re are as defined in claim 1;
n is selected from the group consisting of 0, 1 and 2.

### Claim 12 (depends on 1)

The compound of formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1, being selected from the group consisting of a compound of formula (I-a), a compound of formula (I-b), a compound of formula (II-a), a compound of formula (II-b), a compound of formula (III-a), a compound of formula (III-b), a stereoisomer thereof and a pharmaceutically acceptable salt thereof,
wherein
X, Y, R1, R2, R3, Rb and Re are as defined in claim 1;
n is selected from the group consisting of 0, 1 and 2.

### Claim 13 (depends on 1)

A compound of Formula (I) a stereoisomer thereof or a pharmaceutically acceptable salt thereof according to claim 1, wherein the compound of Formula (I) is selected from the group consisting of:

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the compound, the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 15

(canceled)

### Claim 16 (depends on 6)

The compound according to claim 6, wherein the structural unit
is selected from the group consisting of
optionally, the structural unit
is selected from the group consisting of

### Claim 17 (depends on 1)

The compound according to claim 1, wherein Rc is selected from the group consisting of halogen, hydroxy, amino, C1-3 alkyl, C1-3 alkoxy, C1-3 alkyl-C(O)— and C1-3 alkyl-S(O)2—;
or Rc is selected from the group consisting of halogen, hydroxy and amino;
or Rc is selected from the group consisting of fluorine, chlorine and bromine;
or Rc is selected from bromine.

### Claim 18 (depends on 1)

The compound according to claim 1, wherein Rd is selected from the group consisting of halogen, hydroxy, amino, C1-3 alkyl, C1-3 alkoxy, C1-3 alkyl-C(O)—, C1-3 alkyl-S(O)2—, C3-6 cycloalkyl, 3-6 membered heterocycloalkyl, phenyl and 5-6 membered heteroaryl;
or Rd is selected from the group consisting of halogen, hydroxy, amino, C1-3 alkyl and C1-3 alkoxy;
or Rd is selected from the group consisting of C1-3 alkyl and C1-3 alkoxy;
optionally, Rd is selected from C1-6 alkyl;
or Rd is selected from C1-3 alkyl;
or Rd is selected from the group consisting of methyl, ethyl, n-propyl and isopropyl;
or Rd is selected from methyl.

### Claim 19 (depends on 8)

The compound according to claim 8, wherein R1 and R2 are each independently selected from the group consisting of methyl, ethyl, tert-butyl, cyclopropyl, cyclopentyl, cyclohexyl, phenyl and
or R1 and R2, together with the sulfur atom to which they are attached, form

### Claim 20 (depends on 1)

A method for treating an ATR-related or ATR-mediated disease and/or disorder, comprising administering an effective amount of the compound of Formula (I), the stereoisomer thereof or the pharmaceutically acceptable salt thereof according to claim 1 to a subject in need thereof,
wherein the ATR-related or ATR-mediated disease and/or disorder is optionally a hyperproliferative disease.
